サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1594831

免疫チェックポイント阻害薬（ICI）の世界市場：2024年～2031年

Global Immune Checkpoint Inhibitors (ICIs) Market - 2024-2031

出版日
ページ情報
英文 184 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
免疫チェックポイント阻害薬（ICI）の世界市場：2024年～2031年
出版日: 2024年11月21日
発行: DataM Intelligence
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

免疫チェックポイント阻害薬（ICI）の世界市場は、2023年に401億米ドルに達し、2031年には1,566億米ドルに達すると予測され、予測期間2024年～2031年のCAGRは16.5%で成長する見込みです。

免疫チェックポイントは免疫システムに不可欠な要素であり、健康な細胞に害を及ぼす可能性のある過剰な免疫反応を防ぐように設計されています。これらのチェックポイントは、免疫細胞の一種であるT細胞上のタンパク質が、一部の腫瘍細胞を含む他の細胞上の対応するタンパク質を認識し、結合することで機能します。これらのパートナータンパク質は免疫チェックポイントタンパク質として知られています。チェックポイントタンパク質とそのパートナーが結合すると、T細胞に"オフ "のシグナルが送られ、免疫チェックポイント阻害薬（ICI）を要求するがんを攻撃する免疫系の能力を阻害することができます。

免疫チェックポイント阻害薬（ICI）は、これらのチェックポイントタンパク質とそのパートナーとの相互作用をブロックすることによって機能する免疫療法薬のクラスです。このブロックにより、"オフ "シグナルが伝達されなくなり、T細胞が効果的にがん細胞を標的として排除できるようになります。これらの要因が、世界の免疫チェックポイント阻害薬（ICI）市場拡大の原動力となっています。

市場力学：

促進要因と阻害要因

がん罹患率の増加

がん罹患率の増加が世界の免疫チェックポイント阻害薬（ICI）市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。

がんは急速に進行する疾患であり、死亡率も高いです。近年、標的療法や免疫療法を含む新たな治療アプローチが、手術や放射線のような従来の治療を補完する重要なものとして登場しています。免疫療法の登場は、がん治療を大きく変えました。免疫チェックポイント阻害薬（ICI）の開発により、腫瘍の治療成績は著しく向上しました。

がん免疫学の現在進行中の研究は、がんに対する免疫応答を効果的に刺激できる革新的な薬剤の発見に焦点を当てています。国際がん研究機関（IARC）の2022年のデータによると、新規がん罹患者数は約2,000万人、がん関連死亡者数は約1,000万人です。人口動態予測によれば、2050年までに新規がん罹患者の年間発生率は3,500万人に増加する可能性があり、これは2022年の数字と比べて77％の増加です。このようながん負担の大幅な増加は、免疫チェックポイント阻害薬（ICI）のような効果的な治療オプションに対するニーズの高まりに直結しています。

さらに、この世界の免疫チェックポイント阻害薬（ICI）市場の成長を促進する業界研究調査や主な開発の主要プレーヤー。例えば、2022年2月のNCBI調査によると、最近の研究では、腫瘍に対する免疫反応の最適化におけるいくつかの要因の重要性が強調されています。これらには、排出リンパ節における腫瘍特異的T細胞のプライミングと活性化、その後の腫瘍部位への移動、腫瘍環境内での三次リンパ構造の形成などが含まれます。これらすべての要因が、世界の免疫チェックポイント阻害薬（ICI）市場に需要をもたらしています。

さらに、免疫療法の進歩に対する需要の高まりが、免疫チェックポイント阻害薬（ICI）の世界市場拡大に寄与しています。

治療費の高騰

治療費の高騰は免疫チェックポイント阻害薬（ICI）の世界成長を阻害します。これらの治療に関連する費用は、患者のアクセスを著しく制限し、ヘルスケアシステムに大きな財政的負担を強いる可能性があります。

2023年4月のNCBI調査によると、免疫チェックポイント阻害薬（ICI）の全体的な支出と利用は過去10年間で劇的に急増しました。2011年から2021年にかけて、支出は280万米ドルから41億米ドルに増加しました。同期間、処方件数は94件から2021年には462,049件と大幅に増加し、6種類のICIが含まれます。平均薬価を示す処方箋1枚当たりの平均支出は70％減少し、2011年の約29,795.88ドルから2021年には約8,914.69ドルに減少します。

さらに、治療に関連した毒性の管理にかかる費用全体が、財政状況をさらに複雑にしています。例えば、免疫関連の有害事象の管理は、総治療費に数千ドルを上乗せする可能性があり、これらの治療法の価値対費用比に影響を与えます。その結果、免疫チェックポイント阻害薬（ICI）に関連する高コストは、臨床での採用や利用にとって大きな障壁となります。したがって、上記の要因が免疫チェックポイント阻害薬（ICI）の世界市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がんの発生率増加
    • 抑制要因
      • 治療費の高騰
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 タイプ別

  • PD-1阻害剤
    • ペムブロリズマブ
    • ニボルマブ
    • セミプリマブ
  • PD-L1阻害剤
    • アテゾリズマブ
    • アベルマブ
    • デュルバルマブ
  • CTLA-4阻害剤
    • イピリムマブ
    • トレメリムマブ
  • LAG-3阻害剤（レラトリマブ）
  • その他

第7章 用途別

  • 乳がん
  • 膀胱がん
  • 子宮頸がん
  • 大腸がん
  • ホジキンリンパ腫
  • 肝臓がん
  • 肺がん
  • その他

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第11章 企業プロファイル

  • Bristol-Myers Squibb Company.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Regeneron Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • BeiGene LTD.
  • GSK plc
  • Coherus BioSciences, Inc.
  • lncyte.

第12章 付録

目次
Product Code: PH867

Overview

The global Immune Checkpoint Inhibitors market reached US$ 40.1 billion in 2023 and is expected to reach US$ 156.6 billion by 2031, growing at a CAGR of 16.5% during the forecast period 2024-2031.

Immune checkpoints are integral components of the immune system, designed to prevent an overly aggressive immune response that could harm healthy cells. These checkpoints come into play when proteins on T cells, a type of immune cell, recognize and bind to corresponding proteins on other cells, including some tumor cells. These partner proteins are known as immune checkpoint proteins. When the checkpoint proteins and their partners bind, they send an "off" signal to the T cells, which can inhibit the immune system's ability to attack cancer demands for the Immune checkpoint inhibitors (ICIs).

Immune checkpoint inhibitors (ICIs) are a class of immunotherapy drugs that function by blocking these checkpoint proteins from interacting with their partners. This blockade prevents the "off" signal from being transmitted, thereby enabling T cells to effectively target and eliminate cancer cells. These factors have driven the global immune checkpoint inhibitors (ICIs) market expansion.

Market Dynamics: Drivers & Restraints

Increasing incidence of cancer

The increasing incidence of cancer is significantly driving the growth of the global immune checkpoint inhibitors (ICIs) market and is expected to drive throughout the market forecast period.

Cancer is a rapidly advancing disease with a high mortality rate. In recent years, new therapeutic approaches, including targeted therapies and immunotherapies, have emerged as important complements to traditional treatments like surgery and radiation. The introduction of immunotherapy has significantly transformed cancer management. The development of immune checkpoint inhibitors (ICIs) has notably improved treatment outcomes for tumors.

Ongoing research in cancer immunology is focused on discovering innovative agents that can effectively stimulate immune responses against cancer. According to the International Agency for Research on Cancer (IARC) data in 2022, there were nearly 20 million new cancer cases and approximately 10 million cancer-related deaths. Demographic forecasts suggest that the annual incidence of new cancer cases could rise to 35 million by 2050, representing a 77% increase compared to the figures from 2022. This significant rise in the cancer burden is directly linked to the growing need for effective treatment options, such as immune checkpoint inhibitors (ICIs).

Furthermore, key players in the industry research studies and key developments that would propel this global immune checkpoint inhibitors (ICIs) market growth. For instance, according to the NCBI research study in February 2022, recent research has emphasized the importance of several factors in optimizing the immune response against tumors. These include the priming and activation of tumor-specific T cells in the draining lymph nodes, their subsequent migration to the tumor site, and the formation of tertiary lymphoid structures within the tumor environment. All these factors demand the global immune checkpoint inhibitors (ICIs) market.

Moreover, the rising demand for advancements in immunotherapy contributes to the global immune checkpoint inhibitors (ICIs) market expansion.

High cost of treatments

The high cost of treatments will hinder the growth of global immune checkpoint inhibitors (ICIs). The expenses associated with these therapies can significantly restrict patient access and impose a substantial financial burden on healthcare systems.

As per an NCBI research study in April 2023, overall spending and utilization of immune checkpoint inhibitors (ICIs) have surged dramatically over the past decade. From 2011 to 2021, expenditures rose from $2.8 million to $4.1 billion. During the same period, the number of prescriptions increased significantly, from just 94 to 462,049 in 2021, encompassing six different ICIs. The average spending per prescription indicative of the average drug price decreased by 70%, dropping from approximately $29,795.88 in 2011 to about $8,914.69 in 2021.

In addition, the overall cost of managing treatment-related toxicities further complicates the financial landscape. For instance, managing immune-related adverse events can add thousands of dollars to the total treatment cost, affecting the value-to-cost ratio of these therapies. As a result, the high costs associated with immune checkpoint inhibitors (ICIs) pose a significant barrier to their adoption and utilization in clinical practice. Thus, the above factors could be limiting the global immune checkpoint inhibitors (ICIs) market's potential growth.

Segment Analysis

The global immune checkpoint inhibitors (ICIs) market is segmented based on type, application, distribution channel, and region.

Type:

PD-1 inhibitors segment is expected to dominate the global immune checkpoint inhibitors (ICIs) market share

The PD-1 inhibitors segment holds a major portion of the global immune checkpoint inhibitors (ICIs) market share and is expected to continue to hold a significant portion of the global immune checkpoint inhibitors (ICIs) market share during the forecast period.

PD-1 is a checkpoint protein found in immune cells known as T cells. It functions as an "off switch" that helps prevent T cells from attacking other cells in the body. This occurs when PD-1 binds to PD-L1, a protein present in some normal and cancer cells. When PD-1 attaches to PD-L1, it signals the T cell to leave the other cell unharmed. Many cancer cells produce high levels of PD-L1, which allows them to evade detection by the immune system.

Furthermore, key players in the industry research studies and drug approvals that would drive this segment growth in the global immune checkpoint inhibitors (ICIs) market. For instance, according to the NCBI research study in February 2022, the primary limitation of currently available immune checkpoint inhibitors (ICIs), including PD-1 inhibitors, is that only about 10% to 20% of patients experience significant clinical benefits from these treatments. This low response rate highlights the need for improved strategies to enhance the effectiveness of immunotherapy. One promising approach is to combine different ICIs that have non-overlapping mechanisms of action, which may lead to increased clinical efficacy.

Also, in October 2024, the European Commission approved KEYTRUDA (pembrolizumab) in combination with chemotherapy for two new indications in gynecologic cancers, marking the 30th approval for this anti-PD-1 therapy. This includes the first approval in the European Union (EU) for an anti-PD-1 therapy combined with chemotherapy specifically for patients with primary advanced or recurrent endometrial carcinoma, regardless of their mismatch repair (MMR) status.

The European Commission's approval of KEYTRUDA in combination with chemotherapy for advanced or recurrent endometrial carcinoma underscores the growing role of immune checkpoint inhibitors (ICIs) in oncology. These factors have solidified the segment's position in the global immune checkpoint inhibitors (ICIs) market.

PD-L1 inhibitors segment is the fastest-growing segment in the global immune checkpoint inhibitors (ICIs) market share

The PD-L1 inhibitors segment is the fastest-growing segment in the global immune checkpoint inhibitors (ICIs) market share and is expected to hold the market share over the forecast period.

PD-L1 is a protein that functions as a type of "brake" to regulate the body's immune responses. It is present in some normal cells and is found in elevated levels in certain cancer cells. When PD-L1 binds to PD-1, a protein located in T cells, it signals the T cells to refrain from attacking the PD-L1-expressing cells, including cancer cells. Immune checkpoint inhibitors are anticancer drugs that target PD-L1, blocking its interaction with PD-1. This action effectively releases the "brakes" on the immune system, allowing T cells to recognize and destroy cancer cells.

Monoclonal antibodies that target either PD-1 or PD-L1 can block this interaction, thereby enhancing the immune response against cancer cells. By inhibiting the binding of PD-1 to PD-L1, these therapies reactivate T cells, enabling them to recognize and attack tumors more effectively. These factors have solidified the segment's position in the global immune checkpoint inhibitors (ICIs) market.

Application :

Lung cancer segment is expected to dominate the global immune checkpoint inhibitors (ICIs) market share

The lung cancer segment holds a major portion of the global immune checkpoint inhibitors (ICIs) market share and is expected to continue to hold a significant portion of the global immune checkpoint inhibitors (ICIs) market share during the forecast period.

The incidence of lung cancer needs a substantial demand for effective treatment options, including immune checkpoint inhibitors (ICIs). Lung cancer is a leading cause of mortality, there is an urgent need for therapies that can improve survival rates and quality of life for affected patients.

A recent collaborative report from researchers at the International Agency for Research on Cancer (IARC) and the American Cancer Society (ACS) presents the global cancer statistics for 2022. The report indicates that lung cancer was the most frequently diagnosed cancer globally in 2022, accounting for nearly 2.5 million new cases, which represents about 12.4% of all cancers worldwide. Following lung cancer, breast cancer and colorectal cancer were the next most common, with incidences of 11.6% and 9.6%, respectively. Additionally, lung cancer was the leading cause of cancer-related deaths, responsible for an estimated 1.8 million deaths (approximately 18.7% of total cancer deaths), followed by colorectal cancer (9.3%) and liver cancer (7.8%).

Immune checkpoint inhibitors (ICIs) such as pembrolizumab (Keytruda) and nivolumab (Opdivo) have been approved for the treatment of non-small cell lung cancer (NSCLC), demonstrating improved outcomes compared to traditional therapies. The effectiveness of these drugs in treating lung cancer reinforces their importance in the oncology market and drives investment in further research and development. These factors have solidified the segment's position in the global immune checkpoint inhibitors (ICIs) market.

Bladder cancer segment is the fastest-growing segment in the global immune checkpoint inhibitors (ICIs) market share

The bladder cancer segment is the fastest-growing segment in the global immune checkpoint inhibitors (ICIs) market share and is expected to hold the market share over the forecast period.

Bladder cancer is a major public health issue and is the leading cause of cancer-related deaths worldwide. It ranks as the ninth most common cancer globally and is the second most prevalent urinary tract malignancy, with approximately 549,000 new cases and around 200,000 deaths each year. The incidence and mortality rates for bladder cancer vary significantly across different regions, with the highest rates observed in Western countries, particularly in North America and Europe.

In the United States, bladder cancer is the sixth most frequently diagnosed cancer, accounting for about 3% of all cancers reported globally. In 2023, it is estimated that there will be over 80,000 new cases and more than 16,000 deaths attributed to this disease. The five-year survival rates for bladder cancer are approximately 70% for localized cases, 39.2% for regional cases, and less than 10% for those with distant metastases. Thus, all these factors demand for immune checkpoint inhibitors (ICIs).

According to an NCBI research publication in June 2023, bladder cancer is a prevalent condition with limited treatment options for advanced stages. However, immune checkpoint inhibitors (ICIs) targeting proteins like cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) have shown significant promise in managing this disease. These drugs function by blocking the interactions between receptors and ligands, disrupting the signaling pathways that typically inhibit T cell activity, thus allowing T cells to identify and attack cancer cells more effectively. These factors have solidified the segment's global position in the immune checkpoint inhibitors (ICIs) market.

Geographical Analysis

North America is expected to hold a significant position in the global immune checkpoint inhibitors (ICIs) market share

North America holds a substantial position in the global immune checkpoint inhibitors (ICIs) market and is expected to hold most of the market share.

The rise in cancer cases demands a significant and growing patient population that requires effective treatment options. The increasing burden of cancer directly correlates with the rising demand for immune checkpoint inhibitors (ICIs), which have shown promise in improving patient outcomes across multiple cancer types.

According to National Cancer Institute data in the United States, it is projected that 2,001,140 new cases of cancer will be diagnosed in 2024, alongside an estimated 611,720 deaths from the disease. This high incidence rate underscores the urgent need for innovative therapies, particularly immune checkpoint inhibitors (ICIs), which have demonstrated effectiveness in treating a variety of cancers.

Furthermore, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, technological advancements, & investment in immunotherapy centers, and product launches & approvals would propel this immune checkpoint inhibitor (ICIs) market growth.

For instance, in August 2024, the U.S. Food and Drug Administration (FDA) approved the Immune checkpoint inhibitors (ICIs) drug dostarlimab-gxly (brand name Jemperli) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).

This approval is particularly significant as it expands the use of dostarlimab-gxly beyond its previous indication, which was limited to patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumors. The expansion of dostarlimab-gxly's indications reflects a growing trend in the immune checkpoint inhibitors (ICIs) market towards broader applications of existing therapies. Thus, the above factors are consolidating the region's position as a dominant force in the global immune checkpoint inhibitors (ICIs) market.

Asia Pacific is growing at the fastest pace in the global immune checkpoint inhibitors (ICIs) market

Asia Pacific holds the fastest pace in the global immune checkpoint inhibitors (ICIs) market and is expected to hold most of the market share.

In the Asia-Pacific region, the immune checkpoint inhibitors (ICIs) market is driven by factors such as the increasing prevalence of cancer, growing investments in research and developments related to cancer, increasing innovative and targeted treatment options, and advancements in antibody technologies.

Japan holds a major portion of the market share owing to the rising prevalence of cancer Japan is a significant driver for immune checkpoint inhibitors (ICIs), as these therapies offer targeted treatment options that can be more effective and less toxic than traditional chemotherapies.

This high incidence of cancer cases demands effective treatment options, including immune checkpoint inhibitors, which have shown significant efficacy in treating various cancers. As per Australian Institute of Health and Welfare reported that by 2024, it is projected that approximately 169,500 new cases of cancer will be diagnosed in Australia. This represents an increase of about 93% over the past 24 years, primarily driven by population growth and a rising number of individuals reaching older age groups, which are associated with higher cancer rates. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global immune checkpoint inhibitors (ICIs) market.

Competitive Landscape

The major global players in the immune checkpoint inhibitors (ICIs) market include Bristol-Myers Squibb Company., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, BeiGene LTD., GSK plc, Coherus BioSciences, Inc., and lncyte. among others.

Emerging Players

The emerging players in the global immune checkpoint inhibitors (ICIs) market include Immutep Limited, OncoC4., iTeos Therapeutics., and CureVac SE among others.

Key Developments

  • In June 2024, the U.S. Food and Drug Administration (FDA) approved the Immune checkpoint inhibitors (ICIs) drug durvalumab (brand name Imfinzi) in combination with carboplatin and paclitaxel, followed by single-agent durvalumab, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The FDA's approval of durvalumab in combination with chemotherapy for dMMR advanced or recurrent endometrial cancer underscores the growing role of immune checkpoint inhibitors (ICIs) in oncology.

Why Purchase the Report?

  • To visualize the global immune checkpoint inhibitors (ICIs) market segmentation based on type, application, distribution channel, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the immune checkpoint inhibitors (ICIs) market with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global immune checkpoint inhibitors (ICIs) market report would provide approximately 62 tables, 59 figures, and 184 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Incidence of Cancer
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. PD-1 Inhibitors *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Pembrolizumab
    • 6.2.4. Nivolumab
    • 6.2.5. Cemiplimab
  • 6.3. PD-L1 Inhibitors
    • 6.3.1. Atezolizumab
    • 6.3.2. Avelumab
    • 6.3.3. Durvalumab
  • 6.4. CTLA-4 Inhibitors
    • 6.4.1. Ipilimumab
    • 6.4.2. Tremelimumab
  • 6.5. LAG-3 Inhibitors (Relatlimab)
  • 6.6. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Breast Cancer *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bladder Cancer
  • 7.4. Cervical Cancer
  • 7.5. Colon Cancer
  • 7.6. Hodgkin Lymphoma
  • 7.7. Liver Cancer
  • 7.8. Lung Cancer
  • 7.9. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Bristol-Myers Squibb Company. *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Merck & Co., Inc.
  • 11.3. F. Hoffmann-La Roche Ltd
  • 11.4. AstraZeneca
  • 11.5. Regeneron Pharmaceuticals, Inc.
  • 11.6. Eli Lilly and Company
  • 11.7. BeiGene LTD.
  • 11.8. GSK plc
  • 11.9. Coherus BioSciences, Inc.
  • 11.10. lncyte.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us